{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:13:28Z","timestamp":1779203608706,"version":"3.51.4"},"reference-count":7,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2026,3,14]],"date-time":"2026-03-14T00:00:00Z","timestamp":1773446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,19]]},"abstract":"<jats:p>To date, the primary endpoint of hidradenitis suppurativa (HS) clinical trials is typically a focused lesion count, which has been shown to be error prone and which may not comprehensively measure the inflammatory burden. Unlike lesions of other inflammatory skin diseases such as atopic dermatitis, vitiligo and alopecia areata, HS lesions exhibit substantial morphological heterogeneity. Accordingly, the Investigator Global Assessment of Hidradenitis Suppurativa (I-GLASS) instrument was developed.<\/jats:p>","DOI":"10.1093\/bjd\/ljag083","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T15:50:03Z","timestamp":1773330603000},"page":"1151-1153","source":"Crossref","is-referenced-by-count":0,"title":["Introducing the Investigator Global Assessment of Hidradenitis Suppurativa (I-GLASS) instrument"],"prefix":"10.1093","volume":"194","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5257-1142","authenticated-orcid":false,"given":"John R","family":"Ingram","sequence":"first","affiliation":[{"name":"Division of Infection & Immunity, Cardiff University , Cardiff, UK"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0886-6856","authenticated-orcid":false,"given":"Amit","family":"Garg","sequence":"additional","affiliation":[{"name":"Northwell Health, New Hyde Park , NY ,","place":["USA"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2026,3,23]]},"reference":[{"key":"2026051911031037900_ljag083-B1","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1001\/jamadermatol.2020.5467","article-title":"Global harmonization of morphological definitions in hidradenitis suppurativa for a proposed glossary","volume":"157","author":"Frew","year":"2021","journal-title":"JAMA Dermatol"},{"key":"2026051911031037900_ljag083-B2","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1001\/jamadermatol.2025.4652","article-title":"Standardization of lesion classification and assessment by investigators in clinical trials for hidradenitis suppurativa: a consensus exercise using a modified Delphi approach","volume":"162","author":"Garg","year":"2026","journal-title":"JAMA Dermatol"},{"key":"2026051911031037900_ljag083-B3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/bjd.17716","article-title":"Inter-rater agreement and reliability of outcome measurement instruments and staging systems used in hidradenitis suppurativa","volume":"181","author":"Thorlacius","year":"2019","journal-title":"Br J Dermatol"},{"key":"2026051911031037900_ljag083-B4","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1111\/bjd.13270","article-title":"Assessing the validity, responsiveness and meaningfulness of the Hidradenitis Suppurativa Clinical Response (HiSCR) as the clinical endpoint for hidradenitis suppurativa treatment","volume":"171","author":"Kimball","year":"2014","journal-title":"Br J Dermatol"},{"key":"2026051911031037900_ljag083-B5","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1093\/bjd\/ljae379","article-title":"Intra-rater agreement of lesion counts in hidradenitis suppurativa","volume":"192","author":"Midgette","year":"2025","journal-title":"Br J Dermatol"},{"key":"2026051911031037900_ljag083-B6","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1093\/bjd\/ljad375","article-title":"Addressing high placebo response rates in randomized clinical trials for hidradenitis suppurativa","volume":"190","author":"Garg","year":"2024","journal-title":"Br J Dermatol"},{"key":"2026051911031037900_ljag083-B7","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1111\/bjd.16672","article-title":"A core domain set for hidradenitis suppurativa trial outcomes: an international Delphi process","volume":"179","author":"Thorlacius","year":"2018","journal-title":"Br J Dermatol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljag083\/67359234\/ljag083.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/6\/1151\/67359234\/ljag083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/194\/6\/1151\/67359234\/ljag083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T15:03:17Z","timestamp":1779202997000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/194\/6\/1151\/8524192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,23]]},"references-count":7,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,3,23]]},"published-print":{"date-parts":[[2026,5,19]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljag083","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,6]]},"published":{"date-parts":[[2026,3,23]]}}}